Brand Reference: Myrbetriq
| Metric | Verified Benchmark | Source |
|---|---|---|
| Mirabegron Extended-Release RxNorm Concept ID | 1300786 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $9.4500 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $446.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $48.90 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $55.00 / mo | 14 Zero-PHI Verified Patient Logs |
Selectively activates human beta-3 adrenergic receptors on urinary bladder detrusor smooth muscle during the storage phase (increasing bladder capacity without impairing voiding contraction or inducing anticholinergic cognitive brain fog/xerostomia) while weakly activating brown adipose thermogenesis.
CMS National Average Drug Acquisition Cost (NADAC) tracking places Mirabegron Extended-Release (Myrbetriq, RxCUI 1300786) at $9.4500 per unit, whereas walk-in chain pharmacies bill cash patients an average of $446.00 monthly—creating a 89% ($397.10/mo) wholesale arbitrage spread down to $48.90.
Systemic exposure to Mirabegron Extended-Release reflects 29% (25 mg) to 35% (50 mg) absorption kinetics and butyrylcholinesterase, ugt, cyp3a4, and cyp2d6; moderate cyp2d6 inhibitor, sustaining receptor engagement across a 50 hours half-life window (4–8 weeks urinary urgency/nocturia reduction response profile).
Dosing protocols (25 mg ER PO once daily or 50 mg ER PO once daily) balance efficacy (86.70% patient satisfaction across 14 logs) against mild systolic bp +2 mmhg (9% of reports), nasopharyngitis (7% of reports), headache (5% of reports), with strict avoidance in severe uncontrolled hypertension (bp >= 180/110 mmhg).
Across 14 verified cash-pay logs, Mirabegron Extended-Release achieves a 86.70% Worth-It rating with out-of-pocket spend averaging $55.00/mo versus $446.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 25 mg ER PO once daily for Mirabegron Extended-Release; monthly out-of-pocket dropped to $43.03 compared with $446.00 retail.
Completed 10 weeks on Mirabegron Extended-Release (50 mg ER PO once daily). Zero notable side effects on steady dosing.
Consistent biomarker response on 25 mg ER PO once daily Mirabegron Extended-Release sourced via Local Pharmacy ($56.72/mo cash pay without insurance prior authorization).